Molecular Templates, Inc (MTEM)

Etorro trading 970x250
Molecular Templates, Inc (MTEM) Logo

About Molecular Templates, Inc

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. Its proprietary drug platform technology is engineered toxin bodies (ETBs). The company’s lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed and refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin’s lymphoma. It also develops MT-4019, engineered toxin body targeting CD38; TAK-169 targeting CD38 is in Phase I clinical trial; MT-5111 targeting HER2 is in Phase I clinical trial; and MT-6402 with antigen seeding targeting PD-L1. The company has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma; and a strategic research collaboration with Vertex Pharmaceuticals Incorporated to discover and develop novel targeted biologic therapies for applications outside of oncology; and Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. is headquartered in Austin, Texas. Address: 9301 Amberglen Boulevard, Austin, TX, United States, 78729

Molecular Templates, Inc News and around…

Latest news about Molecular Templates, Inc (MTEM) common stock and company :

4 Penny Stocks Insiders Are Buying
11 Jan, 2022 FinancialContent

When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and ...

63 Biggest Movers From Yesterday
31 Dec, 2021 FinancialContent

Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) shares surged 93.2% to close at $1.70 on Thursday. Kiora Pharmaceuticals ...

12 Health Care Stocks Moving In Thursday's Intraday Session
30 Dec, 2021 FinancialContent

Gainers Kiora Pharmaceuticals (NASDAQ:KPRX) shares increased by 48.3% to $1.3 during Thursday's regular session. Trading volume for ...

44 Stocks Moving In Thursday's Mid-Day Session
30 Dec, 2021 FinancialContent

Gainers Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) jumped 52.3% to $1.3396. Kiora Pharmaceuticals recently appointed David ...

Mid-Day Market Update: Crude Oil Rises 0.5%; Integrated Media Technology Shares Jump
30 Dec, 2021 FinancialContent

Midway through trading Thursday, the Dow traded up 0.04% to 36,504.54 while the NASDAQ rose 0.59% to 15,859.87. The S&P also rose, ...

IEIH's Underlying Holdings Could Mean 34% Gain Potential
08 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

50 Stocks Moving In Wednesday's Mid-Day Session
01 Dec, 2021 FinancialContent

Gainers Arbutus Biopharma Corporation (NASDAQ: ABUS) climbed 91.7% to $6.14 on above-average volume on Wednesday. The Patent Trial ...

Molecular Templates Provides Corporate Update and Outlines 2022 Milestones
30 Nov, 2021 Yahoo! Finance

Unique PD-L1-mediated immune changes and early signs of anti-tumor activity with MT-6402 Continued dose-finding with MT-5111 and MT-0169 Pipeline advancing with IND planned for CTLA-4 program in 2H22 MTEM to Present at Evercore ISI 4th Annual HealthCONx on December 2nd, 2021 AUSTIN, Texas, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc.(Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery and development

Molecular Templates, Inc. Announces Fast Track Designation Granted by FDA for MT-6402
18 Nov, 2021 Yahoo! Finance

AUSTIN, Texas, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for MT-6402 for the treatment of patients with advanced non-small cell lung cancer (NSCLC) expressing PD-L1. “Fa

Molecular Templates is Now Oversold (MTEM)
16 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
16 Nov, 2021 Yahoo! Finance

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Molecular Templates Inc. (MTEM) Reports Q3 Loss, Misses Revenue Estimates
15 Nov, 2021 Yahoo! Finance

Molecular Templates Inc. (MTEM) delivered earnings and revenue surprises of -68.75% and -84.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Molecular Templates Earnings Perspective: Return On Capital Employed
15 Nov, 2021 FinancialContent

Benzinga Pro data, Molecular Templates (NASDAQ:MTEM) reported Q3 sales of $2.38 million. Earnings fell to a loss of $29.53 million, ...

Molecular Templates, Inc. Reports Third Quarter 2021 Financial Results
15 Nov, 2021 Yahoo! Finance

AUSTIN, Texas, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the third quarter of 2021. “We are focused on execution across our growing portfolio of wholly owned next-generation ETBs,” said Eric Poma, Ph.D., Molecular Templates’ Chief E

Analysts Expect 24% Gains Ahead For IEIH
03 Nov, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

Molecular Templates Inc. (MTEM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
28 Oct, 2021 Yahoo! Finance

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates
28 Oct, 2021 Yahoo! Finance

Zacks Industry Outlook Highlights: Xencor, Enanta, Catalyst Pharmaceuticals, and Molecular Templates

12 Health Care Stocks Moving In Monday's Pre-Market Session
18 Oct, 2021 FinancialContent

Gainers Valneva (NASDAQ:VALN) stock increased by 35.65% to $38.05 during Monday's pre-market session. The market ...

Wall Street Analysts Predict a 98% Upside in Molecular Templates Inc. (MTEM): Here's What You Should Know
12 Oct, 2021 Yahoo! Finance

The average of price targets set by Wall Street analysts indicates a potential upside of 98.3% in Molecular Templates Inc. (MTEM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Analysts Forecast 21% Upside For IEIH
30 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Evolved US.

48 Biggest Movers From Friday
27 Sep, 2021 FinancialContent

Gainers ZIVO Bioscience, Inc. (NASDAQ: ZIVO) shares climbed 58% to close at $5.45 on Friday. Clearwater Analytics Holdings, ...

12 Health Care Stocks Moving In Friday's Intraday Session
24 Sep, 2021 FinancialContent

Gainers Molecular Templates (NASDAQ:MTEM) stock rose 14.13% to $7.59 during Friday's regular session. Trading volume ...

Commit To Purchase Molecular Templates At $5, Earn 12.5% Annualized Using Options
24 Sep, 2021 FinancialContent

Investors eyeing a purchase of Molecular Templates Inc (MTEM) shares, but cautious about paying the going market price of $7.58/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the March 2022 put at the $5 strike, which has a bid at the time of this writing of 30 cents..

12 Health Care Stocks Moving In Friday's Pre-Market Session
24 Sep, 2021 FinancialContent

Gainers Cellect Biotechnology (NASDAQ:APOP) stock moved upwards by 251.16% to $21.07 during Friday's pre-market ...

Molecular Templates Inc. (MTEM) Moves 11.8% Higher: Will This Strength Last?
22 Sep, 2021 Yahoo! Finance

Molecular Templates Inc. (MTEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Molecular Templates to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
20 Sep, 2021 FinancialContent
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

2 “Strong Buy” Stocks Trading at Steep Discounts
14 Sep, 2021 Yahoo! Finance

Investing is all about profits, and part of generating profits is knowing when to start the game. The old adage says to buy low and sell high, and while it’s tempting just to discount cliches like that, they’ve passed into common currency because they embody a fundamental truth. Buying low is always a good start in building a portfolio. The trick, however, is recognizing the right stocks to buy low. Prices fall for a reason, and sometimes that reason is fundamental unsoundness. Fortunately, Wall

The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
14 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
10 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Molecular Templates, Inc (MTEM) is a NASDAQ Common Stock listed in , ,

970x250